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Abstract
Background: Oral progesterone is recommended as an alternative to gonadotropin-
releasing hormone (GnRH) agonists and antagonists to prevent luteinizing hormone
(LH) surge in assisted reproductive technology (ART) cycles. However, there are little
data regarding its use.
Objective: We aimed to compare the effect of oral Utrogestan and Cetrotide (a GnRH
antagonist) on preventing LH surge in ART cycles.
Materials and Methods: In this randomized clinical trial, 100 infertile women
undergoing ART who received recombinant follicle-stimulating hormone (FSH) at 150-
225 IU/day were randomly assigned to receive either Utrogestan 100 mg twice a day
(case group) or GnRH antagonist protocol (control group) from cycle day 3 until the
trigger day. Triggering was performed with 10,000 IU hCG) when there were at least
three mature follicles. Viable embryos were cryopreserved for transfer in the next
cycle for both groups. The number of oocytes retrieved and transferred embryos were
compared between groups.
Results: The case group had significantly higher progesterone levels on triggering day,
more follicles of >14 mmwith higher maturity, and more oocytes retrieved with a higher
rate of embryos transferred. A small increase in the pregnancy rate was observed in the
case group, with no significant between-group differences. The most important result
was the lack of premature LH surge in either group upon serum LH assessment on the
triggering day.
Conclusion: Utrogestan is an alternative treatment that could reduce the LH surge
rate and increase the ART outcomes including the number of oocytes retrieved and
transferred embryos compared with GnRH agonists and antagonists.
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1. Introduction
Different assisted reproductive technology
(ART) methods have been used for the treatment
of infertility (1, 2). The success rates of ART have
increased with the use of controlled ovarian
hyperstimulation which increases the number of
oocytes retrieved. However, premature luteinizing
hormone (LH) surge is a great burden that reduces
the treatment efficacy. Gonadotropin-releasing
hormone (GnRH) agonists and antagonists
significantly reduced LH surge in in vitro fertilization
(IVF) cycles (3-5). Zhu and colleagues reported
that progesterone soft capsules (Utrogestan) could
prevent premature LH surge in IVF cycles (6, 7).
This treatment along with hMG protocol had higher
retrieved viable embryo rate per retrieved oocyte
than short protocol. However, few studies have
evaluated the effects of progesterone, including
Utrogestan, on preventing LH surge and improving
ART outcomes.
Progesterone is the primary modulator of GnRH
pulse frequency slowing in women. The increased
progesterone levels in luteal phase causes slowing
of the LH and GnRH pulse frequency, which also
happens in follicular phase after administering
progesterone. The proper level for progesterone
causing LH pulse frequency suppress in productive
women is uncertain (8).
In this study, we aimed to evaluate the effects
of oral Utrogestan in comparison with Cetrotide on
preventing LH surge in ART cycles.
2. Materials and Methods
In this randomized single-blinded controlled
clinical trial, 100 infertile women undergoing IVF
at Al-Zahra Hospital, Tabriz, Iran, were included.
Infertile women aged 20-40 years with an antral
follicle count of >4 on day 3 of the cycle and a
baseline FSH of <15 IU/L were included. If there
was any contraindication for ovarian stimulation
or evidence of ovarian failure, endometriosis
grades III and IV or severe male factor as the
infertility cause the patients were excluded
from the study. Cycles using donor oocytes or
cryopreserved embryos were excluded from this
study. We also excluded women with known
intrauterine anomalies, previous abortion or
curettage, operative hysteroscopy, polypectomy,
myomectomy or septum resection.
Using G*Power software 9.3.2, the sample size
was calculated 46 per condition, considering an
effect size of d ≥ 0.70 as statistically significant
in a two-tailed test with 𝛼 = 0.05 and power
of 0.8. To prevent patient loss during the study
and maintain the study power, we recruited 57
patients for each group. Patients were enrolled in
the study via block randomization (Figure 1). After
being selected, women were randomly allocated
to either the case and control group. All patients
in both groups received recombinant FSH (GonalF,
Merck serono) at 150-225 IU per day since day
2/3 of menstruation until the trigger day. The case
group received Utrogestan 100 mg (Esins health
care) twice a day from day 3 of menstruation,
whereas the control group was treated with GnRH
antagonist protocol. Transvaginal sonography was
performed and after detecting mature follicle (≥
14 mm), Cetrotide 0.25 mg (cetrorelix acetate,
Merck Serono Ltd) was subcutaneously injected
every day until HCG injection day in the control
group. We prescribed 10,000 unit hCG (Pregnyl,
Organon, Netherland) when there were at least
three mature follicles. Oocyte retrieval planned
for 36 hr after hCG triggering, and fertilization
of retrieved oocytes was performed via IVF or
intracytoplasmic sperm injection. In both groups,
viable embryos were cryopreserved for later, which
was performed in the next cycle. A maximum of
three embryos was implanted into each patient.
After implantation, progesterone (in oil; 50 mg)
was administered Intramuscular twice daily to
support luteal function. Pregnancy was confirmed
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by positive serum 𝛽-HCG 14 days after embryo
transfer. The determination of gestational sac(s)
through ultrasonography exam was a sign of
clinical pregnancy. The progesterone and LH
levels at cycle day 3 and trigger day were
measured.
Figure 1. Study Flow diagram.
2.1. Ethical consideration
The ethics committee of the Tabriz University of
Medical Sciences approved this study (code:
IR.TBZMED.REC.1396.363), and all patients
provided informed consent.
2.2. Statistical analysis
The statistical analysis was performed using
SPSS 20 (Statistical Package for the Social
Sciences, SPSS Inc., Chicago, IL, U.S.A.). Results
were presented as mean and standard deviation
(SD) or frequency and percentage. An independent
t-test and chi-squared test were used to compare
the results between groups. P-values of <0.05
were considered significant.
3. Results
As shown in Figure 1, 268 eligible women
were evaluated, and 114 women were included
in the study. Seven women from each group
were excluded owing to failed fertilization or poor
embryos. Finally, 100 women underwent IVF in
the case (n = 50) and control (n = 50) groups.
Table I presents their demographic findings,
with no difference between the groups. The
most common cause of primary infertility was
the tubal factor. The clinical manifestations and
findings following treatment are summarized
in Table II. The case group had significantly
higher LH at day 3 of the cycle, progesterone
at the HCG day, and more follicles of >14
mm with higher maturity. In addition, more
oocytes were retrieved in this group, and
a higher rate of embryos were transferred.
Positive pregnancy tests were higher in the
case group, with no significant difference. LH
levels significantly decreased in both the case
(p < 0.001) and control groups (p = 0.001) at
the HCG injection day compared with baseline.
There was no premature LH surge in either
group.
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Table I. Baseline findings between groups
Case Control P-value
Age (yr)* 30.22 ± 6.20 32.40 ± 6.57 0.09
Primary 39 (78%) 11 (22%)Infertility**
Secondary 33 (66%) 17 (34%)
0.18
Tubal factor 24 (48%) 20 (40%)
Male factor 17 (34%) 24 (48%)Causes of infertility
Unexplained 9 (18%) 6 (12%)
0.34
Basal FSH 5.80 ± 2.16 4.96 ± 1.70 0.03
Previous IVF 3 (6%) 7 (14%) 0.18
1-2 times 2 5
>3 times 1 2
—-
Data presented as Mean ± SD or frequency (percent), * Independent samples t-test; ** Chi-square test
FSH: Follicle-stimulating hormone; IVF: In vitro fertilization
Table II. Clinical manifestations and findings following treatment
Case Control P-value
Day 3 of cycle 7.53 ± 4.85 4.74 ± 2.67 0.001LH*
HCG day 3.88 ± 2.54 2.74 ± 3.23 0.052
Day 3 of cycle 7.75 ± 1.58 0.65 ± 0.10 0.54Progesterone
HCG day 11.14 ± 1.69 0.90 ± 0.18 <0.001
≥14 mm follicles 16.90 ± 7.33 14.12 ± 5.33 0.03
Mature follicles 15.36 ± 7.44 11.82 ± 5.40 0.008
Retrieved oocytes 14.52 ± 6.99 9.90 ± 5.68 <0.001
Oocytes M2 10.82 ± 5.79 6.96 ± 4.22 <0.001
Number of embryos 9.98 ± 5.49 6.78 ± 4.51 0.002
Ovulation cycles days 9.61 ± 1.03 10.36 ± 1.38 0.003
Endometrial thickness 8.07 ± 0.47 7.66 ± 1.57 0.08
Positive pregnancy** 15 (30%) 12 (24%) 0.49
Data presented as Mean ± SD or frequency (percent), * Independent samples t-test; ** Chi-square test
LH: Luteinizing hormone; HCG: Human chorionic gonadotropin
4. Discussion
In this study, we evaluated the effect of
Utrogestan on preventing premature LH surge in
IVF cycles and observed no LH surge in either the
case or control groups.
Premature LH surge is a major problem in
IVF cycles, reducing the efficacy of ovarian
stimulation (9). Different therapies have been
introduced to prevent or reduce LH surge,
including GnRH agonists and antagonists (3-
5). GnRH agonists are accompanied with a
higher rate of ovarian hyperstimulation syndrome,
whereas poor ovarian response and a lower rate
of pregnancy are common with GnRH antagonist
treatments (10). However, progesterone has
been shown to properly reduce LH surge and is
considered a substitute for previous therapies,
particularly with its benefit of being taken orally
rather than injected (11). Previous studies using
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medroxyprogesterone acetate reported no LH
surge among normal responders (12, 13) or women
with PCOS (14). Moreover, similar to our findings,
Zhu and colleagues also reported no LH surge
using Utrogestan (6, 7). One reason for this is
that if administered during the follicular phase,
progesterone can slow LH pulse frequency,
thereby reducing LH levels (15). It has also been
demonstrated that progesterone acts by affecting
progesterone receptors in the hypothalamus,
which suppresses LH surge (13, 16) and its effect is
reversible. Progesterone can be administered via
different routes such as oral, rectal, vaginal, and
intramuscular (17), with all routes showing a similar
efficacy regarding pregnancy, miscarriage, and
live birth rates.
In this study, women treated with Utrogestan
had significantly higher progesterone levels at
the HCG injection day, more follicles of >14
mm with higher maturity, and more retrieved
oocytes with a higher rate of embryos available for
transfer. The pregnancy rate was also higher
in the case group although not significant.
Zhu and colleagues (18) studied the effects of
Utrogestan in women with PCOS and observed
a higher rate of fertilization, a higher rate of
viable embryos per oocyte retrieved, and a higher
pregnancy rate in the Utrogestan group than that
in the control group. However, another study
by Zhu and colleagues (6) that evaluated the
effect of Utrogestan on IVF observed a similar
number of oocytes retrieved with Utrogestan, hMG
protocol, and short protocol, with no significant
difference observed in the mature oocyte rate
or clinical pregnancy rate. Studies comparing
Utrogestan with other forms of progesterone
have demonstrated no drug superiority in terms
of achieving satisfactory results. In a study by
Bergh and colleagues, no difference in the
pregnancy rate between vaginal Utrogestan
and crinone was found (19). Biberoglu and
colleagues also observed no difference on
comparing 300mg and 600mg vaginal Utrogestan
(20).
The better outcome in the Utrogestan group
in both this study and Zhu and colleagues’ study
in women with PCOS could be owing to the fact
that as it is exogenous natural progesterone, it
would induce an autoregulatory positive feedback
action to enhance the production of endogenous
progesterone, as indicated in previous animal
studies (18, 21, 22). Various studies have indicated
that progesterone affects the hypothalamic-
pituitary-ovarian axis for premature LH surge
suppression as well as blocks LH surge induced
by estradiol (23). It has also been reported that
administering progestin during the normal follicular
phase could reduce LH levels in normal women
(24). Thus, progesterone administration could
suppress LH surge in IVF cycles. Compared
with other treatments, Utrogestan can be orally
administered, is well tolerated by users in terms
of lower levels of stress and discomfort, and has
economic benefits.
5. Conclusion
In conclusion, Utrogestan is an alternative
treatment that could reduce the rate of premature
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